Panacea Biotec and Apotex have secured a launch date for the firms’ generic Abraxane (protein-bound paclitaxel) 100mg/vial for injectable suspension in the US and other markets, under a patent-litigation settlement agreement with originator Celgene.
Panacea Biotec and Apotex have secured a launch date for the firms’ generic Abraxane (protein-bound paclitaxel) 100mg/vial for injectable suspension in the US and other markets, under a patent-litigation settlement agreement with originator Celgene.
Apotex, the Indian firm’s marketing partner, will be able to sell generic Abraxane in the US on an undisclosed “mutually...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
